PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$134.44
+4.42%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$129.97
From 52W high−15.24%
Volume611579.00
Market cap$8.70B
P/E (TTM)110.4x
P/S (TTM)30.8x
Div yield—
Key dataOct 19, 2026
Open
$129.97
From 52W high
−15.24%
Volume
611579.00
Market cap
$8.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
92.3x
P/E (TTM)
110.4x
RSI (14)
42.5
MomentumView details →
1D Return
+4.42%
YTD Return
+54.39%
SummaryUpdated Jun 1, 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.
Similar companies
Latest newsMore news →
Protagonist Therapeutics President and CEO Dinesh V. Patel sold 124,000 shares of the company's common stock for approximately $18.2 million between September 8 and September 10, 2026, under a pre-arranged 10b5-1 trading plan.39d agoProtagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.41d ago